NYSE:IBIO iBio (IBIO) Stock Price, News & Analysis $4.41 -0.22 (-4.75%) Closing price 04:00 PM EasternExtended Trading$4.64 +0.23 (+5.10%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About iBio Stock (NYSE:IBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iBio alerts:Sign Up Key Stats Today's Range$4.41▼$4.8650-Day Range$2.83▼$6.4152-Week Range$1.08▼$6.89Volume253,477 shsAverage Volume1.15 million shsMarket Capitalization$43.55 millionP/E RatioN/ADividend YieldN/APrice Target$4.30Consensus RatingBuy Company OverviewiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More… Remove Ads iBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreIBIO MarketRank™: iBio scored higher than 7% of companies evaluated by MarketBeat, and ranked 920th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingiBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageiBio has received no research coverage in the past 90 days.Read more about iBio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iBio are expected to decrease in the coming year, from ($1.74) to ($2.05) per share.Price to Book Value per Share RatioiBio has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IBIO. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for iBio this week, compared to 0 articles on an average week.Search Interest8 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows1 people have added iBio to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, iBio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $74,999.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.58% of the stock of iBio is held by insiders.Percentage Held by InstitutionsOnly 7.90% of the stock of iBio is held by institutions.Read more about iBio's insider trading history. Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Stock News HeadlinesStockNews.com Upgrades iBio (NYSE:IBIO) to "Sell"March 19, 2025 | americanbankingnews.comiBio, Inc. Advances in Therapeutics and LeadershipFebruary 21, 2025 | tipranks.comA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....March 25, 2025 | Banyan Hill Publishing (Ad)iBio to Begin Trading on the Nasdaq Stock ExchangeFebruary 19, 2025 | globenewswire.comIs Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year?February 17, 2025 | msn.comiBio Reports Fiscal Second Quarter 2025 Financial ResultsFebruary 10, 2025 | globenewswire.comiBio Inc. stock falls Monday, still outperforms marketJanuary 27, 2025 | marketwatch.comiBio closes private placement offering with board members, officersJanuary 13, 2025 | markets.businessinsider.comSee More Headlines IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed this year? iBio's stock was trading at $2.45 at the beginning of the year. Since then, IBIO shares have increased by 80.0% and is now trading at $4.41. View the best growth stocks for 2025 here. How were iBio's earnings last quarter? iBio, Inc. (NYSE:IBIO) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.46) EPS for the quarter, meeting analysts' consensus estimates of ($0.46). Who are iBio's major shareholders? iBio's top institutional shareholders include ADAR1 Capital Management LLC (4.23%), Geode Capital Management LLC (0.85%) and Concourse Financial Group Securities Inc.. View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Fastly (FSLY), Fortinet (FTNT), Snowflake (SNOW), Tesla (TSLA), Arbor Realty Trust (ABR) and Accenture (ACN). Company Calendar Last Earnings11/12/2024Today3/25/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:IBIO Previous SymbolNYSE:IBIO CIK1420720 Webwww.ibioinc.com Phone302-355-0650Fax302-356-1173Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$4.30 High Stock Price Target$5.00 Low Stock Price Target$3.60 Potential Upside/Downside-8.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,910,000.00 Net MarginsN/A Pretax Margin-3,795.73% Return on Equity-73.15% Return on Assets-45.51% Debt Debt-to-Equity Ratio0.05 Current Ratio1.76 Quick Ratio1.76 Sales & Book Value Annual Sales$375,000.00 Price / Sales123.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book3.32Miscellaneous Outstanding Shares9,875,000Free Float9,818,000Market Cap$46.18 million OptionableN/A Beta1.29 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NYSE:IBIO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.